berberine and Fatty Liver, Nonalcoholic studies

Research Excerpts

Excerpt	Relevance	Reference
"Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease, NCT00633282 ."	9.41	Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism. ( Chang, X; Gao, J; Ma, S; Wang, L; Wu, W; Xia, M; Yan, H, 2021)
"To explore the therapeutic effect and the hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease."	9.15	[Research on therapeutic effect and hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease]. ( Kong, H; Meng, X; Shu, X; Xie, X; Zhou, X, 2011)
"Berberine (BBR) has been widely used to treat non-alcoholic fatty liver disease (NAFLD)."	8.02	Therapeutic effect of oxyberberine on obese non-alcoholic fatty liver disease rats. ( Chen, HB; Chen, JN; Dou, YX; Huang, XQ; Huang, ZW; Li, QP; Li, YC; Liu, YH; Su, ZR; Xie, JH; Yang, XB; Zeng, HF, 2021)
"This study aimed to explore the therapeutic effects and underlying mechanism of berberine (BBR) on the non-alcoholic fatty liver disease (NAFLD) induced by high-fat diet (HFD)."	7.96	Berberine inhibits liver damage in rats with non-alcoholic fatty liver disease by regulating TLR4/MyD88/NF-κB pathway. ( Jia, Z; Wang, B; Wang, L; Zhang, B, 2020)
"This study aimed to verify the effects of berberine (BBR) on the fat metabolism proteins involved in the sirtuin 3 (SIRT3)/adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK)/acetyl-CoA carboxylase (ACC) pathway in the liver tissues of rats with high-fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD)."	7.91	Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway. ( Chen, RS; Chen, YN; Deng, YJ; Han, L; Jin, L; Liang, S; Liang, YJ; Liang, ZE; Tang, KR; Yang, QH; Zhang, YP, 2019)
"Increasing evidence demonstrates that berberine (BBR) is beneficial for obesity-associated non-alcoholic fatty liver disease (NAFLD)."	7.83	Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet-induced Obesity. ( Botchlett, R; Cai, Y; Chen, L; Guo, T; Guo, X; Huo, Y; Li, H; Li, Q; Li, X; Liu, M; Pei, Y; Woo, SL; Wu, C; Xiao, X; Xu, H; Zeng, T; Zheng, J, 2016)
"To explore the effect of berberine on lipid metabolism disorder and lipid deposition in liver cells of non-alcoholic fatty liver disease (NAFLD) rats induced by high fat diet."	7.81	[Intervention of berberine on lipid deposition in liver cells of non-alcoholic fatty liver disease rats induced by high fat diet]. ( Gong, XW; Han, L; Jin, L; Liang, YJ; Liu, YZ; Wang, PP; Yan, HZ; Yang, QH; Zhang, YP; Zhu, XF, 2015)
"This study was performed to investigate the molecular mechanism and the therapeutic effect of berberine on nonalcoholic fatty liver disease (NAFLD)."	7.77	Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver. ( Hua, YQ; Ji, G; Liu, T; Xing, LJ; Zhang, L; Zheng, PY, 2011)
"To observe the effect of berberine on uncoupling protein-2 (UCP2) mRNA and protein expressions in the hepatic tissue of non-alcoholic fatty liver disease (NAFLD) in rats, and to explore the molecular mechanism."	7.77	Effect of berberine on expressions of uncoupling protein-2 mRNA and protein in hepatic tissue of non-alcoholic fatty liver disease in rats. ( Chen, TY; Hu, SP; Ji, GY; Li, N; Lin, XF; Liu, HT; Qiao, NL; Xie, WN; Yang, QH; Zhang, YP, 2011)
"In this review, we summarize NAFLD, its metabolic and cardiovascular complications, the hepatoprotective effects of BBR due to its broad spectrum of pharmacological effects, and the potential role of BBR in NAFLD therapy."	6.82	Berberine in Non-Alcoholic Fatty Liver Disease-A Review. ( Koperska, A; Moszak, M; Szulińska, M; Wesołek, A, 2022)
"Berberine treatment markedly decreased serum levels of ceramide and ceramide-1-phosphate."	6.82	Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease. ( Bian, H; Chang, X; Gao, X; Jiang, J; Lin, H; Wang, Z; Xia, M; Yan, H; Zhang, J, 2016)
"BBR ameliorates NAFLD and related metabolic disorders."	6.80	Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. ( Chang, XX; Deng, W; Feng, R; Gao, X; Jia, WP; Jiang, JD; Liu, J; Rao, SX; Tu, YF; Wang, Y; Xia, MF; Yan, HM; Yao, XZ; Zeng, MS, 2015)
"Nonalcoholic fatty liver disease (NAFLD) is a globally observed metabolic disease with high prevalence both in adults and children."	6.53	The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease. ( Bian, H; Gao, X; Zhu, X, 2016)
" Furthermore, BSS significantly increased the bioavailability of SIY in both plasma and the liver (2."	6.44	Berberine-silybin salt achieves improved anti-nonalcoholic fatty liver disease effect through regulating lipid metabolism. ( Cui, J; Jiang, J; Li, R; Ma, X; Ren, L; Wang, L; Yu, H; Yu, X; Zhang, W, 2024)
"Nonalcoholic fatty liver disease (NAFLD) is considered to be a manifestation of hepatic metabolic syndrome."	5.72	The combination of berberine and evodiamine ameliorates high-fat diet-induced non-alcoholic fatty liver disease associated with modulation of gut microbiota in rats. ( Dai, Y; Shen, T; Zhou, J; Zhu, W, 2022)
"Nonalcoholic fatty liver disease (NAFLD) has become the most common liver disease worldwide."	5.56	Anti-inflammatory activity of berberine in non-alcoholic fatty liver disease via the Angptl2 pathway. ( Chen, Z; He, B; Lu, Z; Wu, L; Yan, M, 2020)
"Nonalcoholic fatty liver disease (NAFLD) is considered a critical hepatic manifestation of metabolic syndrome."	5.46	Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease. ( Cang, Z; Lu, Y; Nie, X; Sun, H; Wang, N; Zhao, L, 2017)
"Non-alcoholic fatty liver disease (NAFLD) has reached an epidemic level globally, which is recognized to form non-alcoholic steatohepatitis (NASH) by the "two-hit" model, including oxidative stress and inflammation."	5.43	Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress. ( Chen, H; Liu, X; Qiang, X; Wang, Y; Xu, L; Zhang, M; Zhang, P; Zhang, Y; Zhao, Z, 2016)
"Nonalcoholic fatty liver disease (NAFLD) is a common liver disorder that currently lacks effective treatment."	5.42	Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles. ( Gao, X; Li, Y; Tang, X; Wang, J; Xia, P; Yuan, X, 2015)
"Non-alcoholic fatty liver disease (NAFLD) is a multifactorial disease with a complex pathophysiology."	5.42	Effect of a high fat, high sucrose diet on the promotion of non-alcoholic fatty liver disease in male rats: the ameliorative role of three natural compounds. ( Abd Elghaffar, SKh; Badr, G; El-Metwally, TH; Mahmoud, MH; Omar, HM; Ragab, SM, 2015)
"Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease, NCT00633282 ."	5.41	Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism. ( Chang, X; Gao, J; Ma, S; Wang, L; Wu, W; Xia, M; Yan, H, 2021)
"To explore the therapeutic effect and the hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease."	5.15	[Research on therapeutic effect and hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease]. ( Kong, H; Meng, X; Shu, X; Xie, X; Zhou, X, 2011)
"Berberine (BBR) has been widely used to treat non-alcoholic fatty liver disease (NAFLD)."	4.02	Therapeutic effect of oxyberberine on obese non-alcoholic fatty liver disease rats. ( Chen, HB; Chen, JN; Dou, YX; Huang, XQ; Huang, ZW; Li, QP; Li, YC; Liu, YH; Su, ZR; Xie, JH; Yang, XB; Zeng, HF, 2021)
"This study aimed to explore the therapeutic effects and underlying mechanism of berberine (BBR) on the non-alcoholic fatty liver disease (NAFLD) induced by high-fat diet (HFD)."	3.96	Berberine inhibits liver damage in rats with non-alcoholic fatty liver disease by regulating TLR4/MyD88/NF-κB pathway. ( Jia, Z; Wang, B; Wang, L; Zhang, B, 2020)
"Berberine (BBR), a natural compound extracted from Chinese herb, has been shown to effectively attenuate nonalcoholic fatty liver disease (NAFLD) in clinic."	3.91	Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway. ( Bian, H; Chang, X; Gao, X; Li, X; Li, Y; Lu, Y; Sun, X; Wang, L; Xia, M; Xia, P; Xu, X; Yan, H; Zhu, X, 2019)
"This study aimed to verify the effects of berberine (BBR) on the fat metabolism proteins involved in the sirtuin 3 (SIRT3)/adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK)/acetyl-CoA carboxylase (ACC) pathway in the liver tissues of rats with high-fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD)."	3.91	Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway. ( Chen, RS; Chen, YN; Deng, YJ; Han, L; Jin, L; Liang, S; Liang, YJ; Liang, ZE; Tang, KR; Yang, QH; Zhang, YP, 2019)
"Increasing evidence demonstrates that berberine (BBR) is beneficial for obesity-associated non-alcoholic fatty liver disease (NAFLD)."	3.83	Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet-induced Obesity. ( Botchlett, R; Cai, Y; Chen, L; Guo, T; Guo, X; Huo, Y; Li, H; Li, Q; Li, X; Liu, M; Pei, Y; Woo, SL; Wu, C; Xiao, X; Xu, H; Zeng, T; Zheng, J, 2016)
"To explore the effect of berberine on lipid metabolism disorder and lipid deposition in liver cells of non-alcoholic fatty liver disease (NAFLD) rats induced by high fat diet."	3.81	[Intervention of berberine on lipid deposition in liver cells of non-alcoholic fatty liver disease rats induced by high fat diet]. ( Gong, XW; Han, L; Jin, L; Liang, YJ; Liu, YZ; Wang, PP; Yan, HZ; Yang, QH; Zhang, YP; Zhu, XF, 2015)
"To observe the effect of berberine on uncoupling protein-2 (UCP2) mRNA and protein expressions in the hepatic tissue of non-alcoholic fatty liver disease (NAFLD) in rats, and to explore the molecular mechanism."	3.77	Effect of berberine on expressions of uncoupling protein-2 mRNA and protein in hepatic tissue of non-alcoholic fatty liver disease in rats. ( Chen, TY; Hu, SP; Ji, GY; Li, N; Lin, XF; Liu, HT; Qiao, NL; Xie, WN; Yang, QH; Zhang, YP, 2011)
"This study was performed to investigate the molecular mechanism and the therapeutic effect of berberine on nonalcoholic fatty liver disease (NAFLD)."	3.77	Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver. ( Hua, YQ; Ji, G; Liu, T; Xing, LJ; Zhang, L; Zheng, PY, 2011)
"Berberine treatment markedly decreased serum levels of ceramide and ceramide-1-phosphate."	2.82	Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease. ( Bian, H; Chang, X; Gao, X; Jiang, J; Lin, H; Wang, Z; Xia, M; Yan, H; Zhang, J, 2016)
"Nonalcoholic fatty liver disease (NAFLD) is becoming an increasingly serious disease worldwide."	2.82	Targeting lipophagy as a potential therapeutic strategy for nonalcoholic fatty liver disease. ( Li, HY; Peng, ZG, 2022)
"In this review, we summarize NAFLD, its metabolic and cardiovascular complications, the hepatoprotective effects of BBR due to its broad spectrum of pharmacological effects, and the potential role of BBR in NAFLD therapy."	2.82	Berberine in Non-Alcoholic Fatty Liver Disease-A Review. ( Koperska, A; Moszak, M; Szulińska, M; Wesołek, A, 2022)
"BBR ameliorates NAFLD and related metabolic disorders."	2.80	Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. ( Chang, XX; Deng, W; Feng, R; Gao, X; Jia, WP; Jiang, JD; Liu, J; Rao, SX; Tu, YF; Wang, Y; Xia, MF; Yan, HM; Yao, XZ; Zeng, MS, 2015)
"Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world."	2.72	Mechanism of Natural Drugs on Nonalcoholic Fatty Liver Disease. ( Li, L; Xie, J; Zhao, L, 2021)
"Non-alcoholic fatty liver disease (NAFLD) is a clinical condition characterized by lipid infiltration of the liver, highly prevalent in the general population affecting 25% of adults, with a doubled prevalence in diabetic and obese patients."	2.58	Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence. ( Bellentani, S; Cicero, AFG; Colletti, A, 2018)
"Nonalcoholic fatty liver disease (NAFLD) is a globally observed metabolic disease with high prevalence both in adults and children."	2.53	The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease. ( Bian, H; Gao, X; Zhu, X, 2016)
" Furthermore, BSS significantly increased the bioavailability of SIY in both plasma and the liver (2."	2.44	Berberine-silybin salt achieves improved anti-nonalcoholic fatty liver disease effect through regulating lipid metabolism. ( Cui, J; Jiang, J; Li, R; Ma, X; Ren, L; Wang, L; Yu, H; Yu, X; Zhang, W, 2024)
"Nonalcoholic fatty liver disease (NAFLD) is considered to be a manifestation of hepatic metabolic syndrome."	1.72	The combination of berberine and evodiamine ameliorates high-fat diet-induced non-alcoholic fatty liver disease associated with modulation of gut microbiota in rats. ( Dai, Y; Shen, T; Zhou, J; Zhu, W, 2022)
" However, discrepant bioavailability and biodistribution of BER and CUR remained an obstacle to achieve synergistic effects."	1.62	Improving the ameliorative effects of berberine and curcumin combination via dextran-coated bilosomes on non-alcohol fatty liver disease in mice. ( Chen, Y; Du, Q; Gong, Z; Huang, J; Jiang, Z; Lu, Y; Peng, J; Shen, X; Sun, R; Xu, J; Zhang, J; Zhou, J, 2021)
"Berberine (BBR) is an ancient Chinese medicine and has various beneficial effects on metabolic diseases, including NAFLD/NASH."	1.62	Berberine Prevents Disease Progression of Nonalcoholic Steatohepatitis through Modulating Multiple Pathways. ( Chen, W; Gurley, EC; Hylemon, PB; Kakiyama, G; Lai, G; Liu, J; Pandak, WM; Tai, YL; Wang, X; Wang, Y; Yan, J; Zhang, Y; Zhao, D; Zhou, H, 2021)
"Nonalcoholic fatty liver disease (NAFLD) has become the most common liver disease worldwide."	1.56	Anti-inflammatory activity of berberine in non-alcoholic fatty liver disease via the Angptl2 pathway. ( Chen, Z; He, B; Lu, Z; Wu, L; Yan, M, 2020)
"Non‑alcoholic fatty liver disease (NAFLD), which affects approximately one‑third of the general population, has become a global health problem."	1.48	Inhibition of CCL19 benefits non‑alcoholic fatty liver disease by inhibiting TLR4/NF‑κB‑p65 signaling. ( Gao, S; Huang, D; Huang, J; Tong, P; Wang, Y; Wu, X; Yue, Y; Zhao, J, 2018)
" NAFLD model was established by high fat food, and rats were administrated with lovastatin, berberine, curcumin, berberine + curcumin at the dosage of 100, 100, 100, 50 + 50 mg/kg bw, respectively."	1.48	Natural products berberine and curcumin exhibited better ameliorative effects on rats with non-alcohol fatty liver disease than lovastatin. ( Feng, WW; Kuang, SY; Liu, TS; Ma, ZJ; Pang, JY; Tu, C; Wang, JB; Wang, YH; Xiao, XH; Zang, QC; Zhao, YL, 2018)
"Nonalcoholic fatty liver disease (NAFLD) is considered a critical hepatic manifestation of metabolic syndrome."	1.46	Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease. ( Cang, Z; Lu, Y; Nie, X; Sun, H; Wang, N; Zhao, L, 2017)
"The histological spectrum of nonalcoholic fatty liver diseases (NAFLD) ranges from hepatic steatosis to steatohepatitis and fibrosis."	1.43	Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress. ( Cai, D; Jin, L; Li, B; Meng, X; Ning, G; Wang, J; Yang, J; Yao, S; Zhang, H; Zhang, Y; Zhang, Z, 2016)
"Non-alcoholic fatty liver disease (NAFLD) has reached an epidemic level globally, which is recognized to form non-alcoholic steatohepatitis (NASH) by the "two-hit" model, including oxidative stress and inflammation."	1.43	Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress. ( Chen, H; Liu, X; Qiang, X; Wang, Y; Xu, L; Zhang, M; Zhang, P; Zhang, Y; Zhao, Z, 2016)
"Non-alcoholic fatty liver disease (NAFLD) is a multifactorial disease with a complex pathophysiology."	1.42	Effect of a high fat, high sucrose diet on the promotion of non-alcoholic fatty liver disease in male rats: the ameliorative role of three natural compounds. ( Abd Elghaffar, SKh; Badr, G; El-Metwally, TH; Mahmoud, MH; Omar, HM; Ragab, SM, 2015)
"Nonalcoholic fatty liver disease (NAFLD) is a common liver disorder that currently lacks effective treatment."	1.42	Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles. ( Gao, X; Li, Y; Tang, X; Wang, J; Xia, P; Yuan, X, 2015)

Research

Studies (48)

Authors

Clinical Trials (5)

Trial Overview

Trial Outcomes

Absolute Change in Liver Fat Content (LFC) as Measured by MRI-PDFF

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	25 (52.08)	24.3611
2020's	23 (47.92)	2.80

Authors	Studies
Harrison, SA	1
Gunn, N	1
Neff, GW	1
Kohli, A	1
Liu, L	1
Flyer, A	1
Goldkind, L	1
Di Bisceglie, AM	1
Shan, MY	1
Dai, Y	2
Ren, XD	1
Zheng, J	2
Zhang, KB	1
Chen, B	1
Yan, J	2
Xu, ZH	1
Li, HY	1
Peng, ZG	1
Geng, Q	1
Zhang, P	2
Liu, X	2
Xue, L	1
Ke, X	1
Zhang, R	1
Li, P	1
Zuo, L	1
Wang, M	1
Yang, J	2
Wang, J	3
Zhu, W	1
Zhou, J	2
Shen, T	1
Koperska, A	1
Wesołek, A	1
Moszak, M	1
Szulińska, M	1
Wang, H	1
Zhang, H	2
Gao, Z	1
Zhang, Q	1
Gu, C	1
Zhou, LM	1
Fan, JH	1
Xu, MM	1
Xiong, MY	1
Wang, QJ	1
Chai, X	2
Li, XD	1
Li, XG	1
Ye, XL	1
Ye, C	1
Zhang, Y	7
Lin, S	1
Chen, Y	2
Wang, Z	2
Feng, H	1
Fang, G	1
Quan, S	1
He, H	1
Li, J	3
Li, C	1
Wu, X	2
Ye, X	1
Ma, H	1
Li, X	4
Ma, X	1
Yu, X	1
Li, R	2
Cui, J	1
Yu, H	1
Ren, L	1
Jiang, J	2
Zhang, W	1
Wang, L	4
Wang, Y	7
Zhou, X	2
Zhao, D	2
Wang, X	2
Gurley, EC	2
Liu, R	1
Hylemon, PB	2
Chen, W	2
Zhou, H	2
Li, DH	1
Liu, YT	1
Hao, SR	1
Zheng, JM	1
Hou, HT	1
Wang, YZ	1
Lu, Z	2
He, B	2
Chen, Z	2
Yan, M	2
Wu, L	3
Lu, F	1
Yan, H	4
Wu, W	1
Chang, X	4
Xia, M	4
Ma, S	1
Gao, J	1
Tai, YL	1
Kakiyama, G	1
Liu, J	4
Lai, G	1
Pandak, WM	1
Jia, Z	1
Wang, B	1
Zhang, B	1
Xie, J	1
Li, L	1
Zhao, L	2
Li, QP	1
Dou, YX	1
Huang, ZW	1
Chen, HB	1
Li, YC	1
Chen, JN	1
Liu, YH	1
Huang, XQ	1
Zeng, HF	1
Yang, XB	1
Su, ZR	1
Xie, JH	1
Wen, J	1
Liu, D	1
Qiu, Z	1
Zhu, Q	1
Jiang, Z	1
Xu, J	1
Zhang, J	2
Sun, R	1
Lu, Y	4
Gong, Z	1
Huang, J	2
Shen, X	1
Du, Q	1
Peng, J	1
Sahebkar, A	1
Watts, GF	1
Sun, Y	1
Yuan, X	2
Zhang, F	1
Han, Y	1
Xu, X	3
Li, Y	4
Gao, X	8
Feng, WW	1
Kuang, SY	1
Tu, C	1
Ma, ZJ	1
Pang, JY	1
Wang, YH	1
Zang, QC	1
Liu, TS	1
Zhao, YL	1
Xiao, XH	1
Wang, JB	1
Liang, H	1
Cicero, AFG	1
Colletti, A	1
Bellentani, S	1
Zhao, J	1
Tong, P	1
Yue, Y	1
Gao, S	1
Huang, D	1
Zhu, XP	1
Bai, JY	1
Xia, P	3
Li, XY	1
Zhang, YP	3
Deng, YJ	1
Tang, KR	1
Chen, RS	1
Liang, S	1
Liang, YJ	2
Han, L	2
Jin, L	3
Liang, ZE	1
Chen, YN	1
Yang, QH	3
Duan, Y	1
Zhang, L	2
Jiang, H	1
Hu, X	1
Gu, Y	1
Shi, H	1
Zhu, X	2
Bian, H	3
Sun, X	1
Tang, X	1
Yan, HZ	1
Zhu, XF	1
Gong, XW	1
Wang, PP	1
Liu, YZ	1
Ragab, SM	1
Abd Elghaffar, SKh	1
El-Metwally, TH	1
Badr, G	1
Mahmoud, MH	1
Omar, HM	1
Yan, HM	1
Xia, MF	1
Chang, XX	1
Yao, XZ	1
Rao, SX	1
Zeng, MS	1
Tu, YF	1
Feng, R	1
Jia, WP	1
Deng, W	1
Jiang, JD	1
Zhang, Z	2
Li, B	1
Meng, X	2
Yao, S	1
Cai, D	1
Ning, G	1
Cao, Y	1
Pan, Q	1
Cai, W	1
Shen, F	1
Chen, GY	1
Xu, LM	1
Fan, JG	1
Guo, T	1
Woo, SL	1
Guo, X	1
Li, H	1
Botchlett, R	1
Liu, M	1
Pei, Y	1
Xu, H	1
Cai, Y	1
Zeng, T	1
Chen, L	1
Li, Q	1
Xiao, X	1
Huo, Y	1
Wu, C	1
Qiang, X	1
Xu, L	1
Zhang, M	1
Zhao, Z	1
Chen, H	1
Lin, H	1
Choi, YJ	1
Lee, KY	1
Jung, SH	1
Kim, HS	1
Shim, G	1
Kim, MG	1
Oh, YK	1
Oh, SH	1
Jun, DW	1
Lee, BH	1
Cang, Z	1
Sun, H	1
Nie, X	1
Wang, N	1
Hu, SP	1
Xie, WN	1
Li, N	1
Ji, GY	1
Qiao, NL	1
Lin, XF	1
Chen, TY	1
Liu, HT	1
Xing, LJ	1
Liu, T	1
Hua, YQ	1
Zheng, PY	1
Ji, G	1
Xie, X	1
Shu, X	1
Kong, H	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adults With NASH and T2DM[NCT03656744]	Phase 2	101 participants (Actual)	Interventional	2018-11-26	Completed
Assess the Effects of Berberine in Reducing Abdominal Visceral Adipose Tissue Among Individuals With Obesity and Non-alcoholic Fatty Liver Disease[NCT05647915]	Phase 4	326 participants (Anticipated)	Interventional	2022-12-15	Not yet recruiting
Role of Pioglitazone and Berberine in Treatment of Non-alcoholic Fatty Liver Disease(NAFLD) Patients With Impaired Glucose Regulation or Type 2 Diabetes Mellitus[NCT00633282]	Phase 2	184 participants (Actual)	Interventional	2008-03-31	Completed
Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial[NCT03198572]	Phase 4	120 participants (Anticipated)	Interventional	2017-08-16	Recruiting
The Study of Berberine Affecting Metabolism, Inflammation Status, Endothelial Function and Thrombotic Events in Patients With Coronary Artery Disease by Remodeling Gut Microbiota[NCT04434365]	Phase 1/Phase 2	24 participants (Actual)	Interventional	2019-06-21	Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The primary endpoint was the absolute change in liver fat content (LFC) as measured by magnetic resonance imaging derived proton density fat fraction (MRI-PDFF) from Baseline to Week 18. (NCT03656744)
Timeframe: Baseline through study Week 18

Change in ALT

Intervention	Change in percentage of liver fat (Mean)
500mg HTD1801, Bid	-2.918
1000mg HTD1801, Bid	-4.829
Placebo, Bid	-1.962

Absolute change in alanine aminotransferase (ALT) from Baseline to Week 18. (NCT03656744)
Timeframe: Baseline through study week 18

Change in AST

Intervention	U/L (Mean)
500mg HTD1801, Bid	-4
1000mg HTD1801, Bid	-19
Placebo, Bid	-3

Absolute change in aspartate aminotransferase (AST) from Baseline to Week 18. (NCT03656744)
Timeframe: Baseline through study week 18

Change in ELF Score

Intervention	U/L (Mean)
500mg HTD1801, Bid	0
1000mg HTD1801, Bid	-13
Placebo, Bid	-3

Change in the enhanced liver fibrosis (ELF) score. The ELF score is calculated using a published algorithm combining the values of a set of extracellular matrix markers, including TIMP-1, PIIINP, and HA. The ELF score has been reported to show good correlations with fibrosis stages in chronic liver disease, with higher ELF scores associated with higher fibrosis stages. The ELF score is hence used as a prognostic marker for disease progression: ELF score < 9.8 : Low risk of progression, ELF score 9.8 to < 11.3 : Moderate risk of progression and ELF score > = 11.3 : High risk of progression. (NCT03656744)
Timeframe: Baseline through study week 18

Change in Fasting Glucose

Intervention	score on a scale (Mean)
500mg HTD1801, Bid	0.05
1000mg HTD1801, Bid	-0.10
Placebo, Bid	-0.05

Change in fasting glucose from Baseline to Week 18 . (NCT03656744)
Timeframe: Baseline through study Week 18

Change in FGF19

Intervention	mg/dL (Mean)
500mg HTD1801, Bid	120
1000mg HTD1801, Bid	129
Placebo, Bid	131

Change in fibroblast growth factor 19 (FGF19) from Baseline to Week 18 (NCT03656744)
Timeframe: Baseline through study week 18

Change in HA

Intervention	μmol/L (Mean)
500mg HTD1801, Bid	-11
1000mg HTD1801, Bid	-9
Placebo, Bid	-40

Change in hyaluronic acid (HA) from Baseline to Week 18. (NCT03656744)
Timeframe: Baseline through study week 18

Change in HDL-c

Intervention	µg/L (Mean)
500mg HTD1801, Bid	-0.64
1000mg HTD1801, Bid	-5.25
Placebo, Bid	-3.83

Change in high-density lipoprotein cholesterol (HDL-c) from Baseline to Week 18. (NCT03656744)
Timeframe: Baseline through study week 18

Change in HOMA-IR

Intervention	mg/dL (Mean)
500mg HTD1801, Bid	1
1000mg HTD1801, Bid	0
Placebo, Bid	0

Change in homeostasis model assessment-estimated insulin resistance (HOMA-IR) from Baseline to Week 18. The higher the HOMA-IR score, the more insulin resistant a person is. Values of <1 are considered optimal while values >2.9 indicate significant insulin resistance. (NCT03656744)
Timeframe: Baseline through study week 18

Change in LDL-c

Intervention	score on a scale (Mean)
500mg HTD1801, Bid	-3.38
1000mg HTD1801, Bid	-4.21
Placebo, Bid	-6.66

Change in low-density lipoprotein cholesterol (LDL-c) from Baseline to Week 18. (NCT03656744)
Timeframe: Baseline visit through study week 18

Change in PIIINP

Intervention	mg/dL (Mean)
500mg HTD1801, Bid	5
1000mg HTD1801, Bid	-16
Placebo, Bid	0

Change in N-terminal pro-peptide of type III collagen (PIIINP) from Baseline to Week 18. (NCT03656744)
Timeframe: Baseline through study week 18

Change in Pro-Peptide of Type III Collagen (Pro-C3)

Intervention	µg/L (Mean)
500mg HTD1801, Bid	0.68
1000mg HTD1801, Bid	0.03
Placebo, Bid	-0.31

Change in Pro-C3 from Baseline to Week 18 for subjects with elevated Pro-C3 at Baseline. (NCT03656744)
Timeframe: Baseline through study week 18

Change in Serum Triglycerides

Intervention	ng/mL (Mean)
500mg HTD1801, Bid	0.5
1000mg HTD1801, Bid	-2.3
Placebo, Bid	-0.8

Change in serum triglycerides from Baseline to Week 18. (NCT03656744)
Timeframe: Baseline through study week 18

Change in TIMP-1

Intervention	mg/dL (Mean)
500mg HTD1801, Bid	-41
1000mg HTD1801, Bid	-24
Placebo, Bid	18

Change in tissue inhibitor of metalloproteinases 1 (TIMP-1) from Baseline to Week 18. (NCT03656744)
Timeframe: Baseline through study week 18

Change in Total Bile Acids

Intervention	µg/L (Mean)
500mg HTD1801, Bid	1.8
1000mg HTD1801, Bid	-8.9
Placebo, Bid	-6.0

Changes in total bile acids from Baseline to Week 18. (NCT03656744)
Timeframe: Baseline through study week 18

Changes in Hemoglobin A1c

Intervention	μmol/L (Mean)
500mg HTD1801, Bid	1307
1000mg HTD1801, Bid	1625
Placebo, Bid	-581

Changes in HbA1c from Baseline to Week 18. (NCT03656744)
Timeframe: Baseline through study week 18

Number of Participants Reporting an Adverse Events From Baseline Through Week 18

Intervention	Percentage (Mean)
500mg HTD1801, Bid	-0.3
1000mg HTD1801, Bid	-0.6
Placebo, Bid	0.1

AEs were mapped to MedDRA version 20.1 preferred term (PT) and system organ class (SOC). If the subject experienced multiple events that mapped to a single preferred term, the greatest severity grade according to CTCAE Version 4.0, and strongest investigator assessment of relation to study medication was assigned to the preferred term. If an event had a missing severity or relationship, it was classified as having the highest severity and/or strongest relationship to study medication. The occurrence of TEAEs was summarized by treatment group by SOC, PT, and severity. Separate summaries of treatment-emergent serious adverse events (SAEs), TEAEs related to study drug, severe or life threatening TEAEs, and TEAEs leading to the discontinuation of study treatment were generated. Additionally, the occurrence of liver-specific AEs was summarized by treatment group. All reported adverse events were listed for individual subjects showing verbatim term, PT and SOC. (NCT03656744)
Timeframe: Adverse events were collected from the time the subject signed the informed consent form through the date of the last visit for a specific subject, that is, approximately 24 weeks in total for a completed subject.

Number of Subjects Who Achieved ≥5% Absolute Reduction in Liver Fat Content (LFC) as Measured by MRI-PDFF

Intervention	Participants (Count of Participants)
500mg HTD1801, Bid	21
1000mg HTD1801, Bid	26
Placebo, Bid	20

Number of subjects who achieved ≥5% absolute reduction in liver fat content (LFC) as measured by magnetic resonance imaging derived proton density fat fraction (MRI-PDFF) from Baseline to Week 18. (NCT03656744)
Timeframe: Baseline through study Week 18

Number of Subjects Who Normalized LFC to <5% as Measured by MRI-PDFF

Intervention	Participants (Count of Participants)
500mg HTD1801, Bid	10
1000mg HTD1801, Bid	12
Placebo, Bid	8

Number of subjects who normalized liver fat content (LFC) to <5% as measured by magnetic resonance imaging derived proton density fat fraction (MRI-PDFF) at Week 18. (NCT03656744)
Timeframe: Baseline through study Week 18

Proportion of Subjects Who Achieved ≥ 30% Relative Reduction in LFC as Measured by MRI-PDFF

Intervention	Participants (Count of Participants)
500mg HTD1801, Bid	1
1000mg HTD1801, Bid	0
Placebo, Bid	0

Proportion of subjects who achieved ≥ 30% relative reduction in liver fat content (LFC) as measured by magnetic resonance imaging derived proton density fat fraction (MRI-PDFF) from Baseline to Week 18. (NCT03656744)
Timeframe: Baseline through study week 18

Proportion of Subjects With Elevated ALT at Baseline Who Normalized ALT at Week 18

Intervention	Participants (Count of Participants)
500mg HTD1801, Bid	6
1000mg HTD1801, Bid	10
Placebo, Bid	7

Proportion of subjects with elevated alanine aminotransferase (ALT) at Baseline who normalized ALT at Week 18. (NCT03656744)
Timeframe: Baseline through study week 18

Relative Change in LFC as Measured by MRI-PDFF

Intervention	Participants (Count of Participants)
500mg HTD1801, Bid	3
1000mg HTD1801, Bid	9
Placebo, Bid	5

Relative change in liver fat content (LFC) as measured by magnetic resonance imaging derived proton density fat fraction (MRI-PDFF) from Baseline to Week 18. (NCT03656744)
Timeframe: Baseline through study week 18

Article	Year
Targeting lipophagy as a potential therapeutic strategy for nonalcoholic fatty liver disease. Biochemical pharmacology, 2022, Volume: 197 Topics: Animals; Autophagosomes; Autophagy; Berberine; Drug Delivery Systems; Fatty Acids, Nonesterified; Fi	2022
Berberine in Non-Alcoholic Fatty Liver Disease-A Review. Nutrients, 2022, Aug-23, Volume: 14, Issue:17 Topics: Berberine; Gluconeogenesis; Humans; Insulin Resistance; Lipogenesis; Liver; Non-alcoholic Fatty Live	2022
The mechanism of berberine alleviating metabolic disorder based on gut microbiome. Frontiers in cellular and infection microbiology, 2022, Volume: 12 Topics: Bacteria; Berberine; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Humans; Non-alcoholic F	2022
Mechanism of Natural Drugs on Nonalcoholic Fatty Liver Disease. Mini reviews in medicinal chemistry, 2021, Volume: 21, Issue:19 Topics: Berberine; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Liver; Non-alcoholic Fatty Liver D	2021
Mode of action of berberine on lipid metabolism: a new-old phytochemical with clinical applications? Current opinion in lipidology, 2017, Volume: 28, Issue:3 Topics: Animals; Berberine; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Lipid Metabolism; Lipids; Non-	2017
Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence. Nutrients, 2018, Aug-23, Volume: 10, Issue:9 Topics: Antioxidants; Berberine; Curcumin; Dietary Supplements; Fatty Acids, Omega-3; Fatty Acids, Unsaturat	2018
The Potential Mechanisms of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease. Molecules (Basel, Switzerland), 2016, Oct-14, Volume: 21, Issue:10 Topics: AMP-Activated Protein Kinases; Animals; Berberine; Clinical Trials as Topic; DNA Damage; Gene Expres	2016

Article	Year
A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. Nature communications, 2021, 09-17, Volume: 12, Issue:1 Topics: Adiposity; Adult; Aged; Berberine; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; L	2021
A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. Nature communications, 2021, 09-17, Volume: 12, Issue:1 Topics: Adiposity; Adult; Aged; Berberine; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; L	2021
A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. Nature communications, 2021, 09-17, Volume: 12, Issue:1 Topics: Adiposity; Adult; Aged; Berberine; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; L	2021
A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. Nature communications, 2021, 09-17, Volume: 12, Issue:1 Topics: Adiposity; Adult; Aged; Berberine; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; L	2021
Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism. Biology of sex differences, 2021, 01-04, Volume: 12, Issue:1 Topics: Berberine; Diabetes Mellitus, Type 2; Female; Glucose; Humans; Male; Non-alcoholic Fatty Liver Disea	2021
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. PloS one, 2015, Volume: 10, Issue:8 Topics: Adiposity; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Dis	2015
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. PloS one, 2015, Volume: 10, Issue:8 Topics: Adiposity; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Dis	2015
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. PloS one, 2015, Volume: 10, Issue:8 Topics: Adiposity; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Dis	2015
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. PloS one, 2015, Volume: 10, Issue:8 Topics: Adiposity; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Dis	2015
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. PloS one, 2015, Volume: 10, Issue:8 Topics: Adiposity; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Dis	2015
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. PloS one, 2015, Volume: 10, Issue:8 Topics: Adiposity; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Dis	2015
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. PloS one, 2015, Volume: 10, Issue:8 Topics: Adiposity; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Dis	2015
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. PloS one, 2015, Volume: 10, Issue:8 Topics: Adiposity; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Dis	2015
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. PloS one, 2015, Volume: 10, Issue:8 Topics: Adiposity; Administration, Oral; Animals; Berberine; Blood Glucose; Body Weight; Diet, High-Fat; Dis	2015
Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease. Journal of translational medicine, 2016, 09-15, Volume: 14 Topics: Berberine; Biomarkers; Discriminant Analysis; Energy Metabolism; Female; Humans; Least-Squares Analy	2016
[Research on therapeutic effect and hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2011, Volume: 36, Issue:21 Topics: Adult; Alanine Transaminase; Berberine; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Fatty Live	2011

Article	Year
Berberine mitigates nonalcoholic hepatic steatosis by downregulating SIRT1-FoxO1-SREBP2 pathway for cholesterol synthesis. Journal of integrative medicine, 2021, Volume: 19, Issue:6 Topics: Berberine; Cholesterol; Forkhead Box Protein O1; Humans; Non-alcoholic Fatty Liver Disease; Sirtuin	2021
Effect of berberine and bicyclol on Chinese patients with nonalcoholic fatty liver disease: a retrospective study. Postgraduate medicine, 2022, Volume: 134, Issue:5 Topics: Berberine; Biphenyl Compounds; China; Humans; Lipids; Liver; Non-alcoholic Fatty Liver Disease; Retr	2022
Hydrochloride Berberine ameliorates alcohol-induced liver injury by regulating inflammation and lipid metabolism. Biochemical and biophysical research communications, 2022, 06-25, Volume: 610 Topics: AMP-Activated Protein Kinases; Animals; Berberine; Chemical and Drug Induced Liver Injury, Chronic;	2022
The combination of berberine and evodiamine ameliorates high-fat diet-induced non-alcoholic fatty liver disease associated with modulation of gut microbiota in rats. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2022, Volume: 55 Topics: Animals; Berberine; Diet, High-Fat; Gastrointestinal Microbiome; Liver; Mice; Mice, Inbred C57BL; No	2022
Epiberberine regulates lipid synthesis through SHP (NR0B2) to improve non-alcoholic steatohepatitis. Biochimica et biophysica acta. Molecular basis of disease, 2023, Volume: 1869, Issue:4 Topics: Animals; Berberine; Lipids; Mice; Non-alcoholic Fatty Liver Disease	2023
Berberine Ameliorates Metabolic-Associated Fatty Liver Disease Mediated Metabolism Disorder and Redox Homeostasis by Upregulating Clock Genes: Clock and Bmal1 Expressions. Molecules (Basel, Switzerland), 2023, Feb-16, Volume: 28, Issue:4 Topics: Animals; ARNTL Transcription Factors; Berberine; Glucosamine; Hep G2 Cells; Homeostasis; Humans; Hyd	2023
LCN2 contributes to the improvement of nonalcoholic steatohepatitis by 8-Cetylberberine. Life sciences, 2023, May-15, Volume: 321 Topics: Animals; Berberine; Diet, High-Fat; Disease Models, Animal; Inflammation; Lipids; Lipocalin-2; Liver	2023
Berberine-silybin salt achieves improved anti-nonalcoholic fatty liver disease effect through regulating lipid metabolism. Journal of ethnopharmacology, 2024, Jan-30, Volume: 319, Issue:Pt 2 Topics: Animals; Berberine; Fatty Acids; Lipid Metabolism; Lipids; Liver; Mice; Non-alcoholic Fatty Liver Di	2024
Berberine inhibits free fatty acid and LPS-induced inflammation via modulating ER stress response in macrophages and hepatocytes. PloS one, 2020, Volume: 15, Issue:5 Topics: Animals; Berberine; Cytokines; Endoplasmic Reticulum Stress; Hepatocytes; Inflammation; Lipopolysacc	2020
[Discussion on the curative effect and mechanisms of berberine in rats with non-alcoholic fatty liver]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2020, Apr-20, Volume: 28, Issue:4 Topics: Animals; Berberine; Diet, High-Fat; Liver; Non-alcoholic Fatty Liver Disease; Random Allocation; Rat	2020
Anti-inflammatory activity of berberine in non-alcoholic fatty liver disease via the Angptl2 pathway. BMC immunology, 2020, 05-19, Volume: 21, Issue:1 Topics: Angiopoietin-Like Protein 2; Angiopoietin-like Proteins; Animals; Anti-Inflammatory Agents; Berberin	2020
Berberine attenuates non-alcoholic steatohepatitis by regulating chemerin/CMKLR1 signalling pathway and Treg/Th17 ratio. Naunyn-Schmiedeberg's archives of pharmacology, 2021, Volume: 394, Issue:2 Topics: Animals; Anti-Inflammatory Agents; Berberine; Chemokines; Lipid Metabolism; Liver; Male; Non-alcohol	2021
Berberine Prevents Disease Progression of Nonalcoholic Steatohepatitis through Modulating Multiple Pathways. Cells, 2021, 01-21, Volume: 10, Issue:2 Topics: Animals; Berberine; Bile Acids and Salts; Diet, Western; Disease Progression; Fatty Acids; Gene Expr	2021
Berberine inhibits liver damage in rats with non-alcoholic fatty liver disease by regulating TLR4/MyD88/NF-κB pathway. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2020, Volume: 31, Issue:12 Topics: Animals; Berberine; Diet, High-Fat; Disease Models, Animal; Drugs, Chinese Herbal; Liver; Male; Myel	2020
Therapeutic effect of oxyberberine on obese non-alcoholic fatty liver disease rats. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2021, Volume: 85 Topics: Adipose Tissue, White; AMP-Activated Protein Kinase Kinases; Animals; Berberine; Diet, High-Fat; Hom	2021
Demethylenetetrahydroberberine alleviates nonalcoholic fatty liver disease by inhibiting the NLRP3 inflammasome and oxidative stress in mice. Life sciences, 2021, Sep-15, Volume: 281 Topics: Animals; Berberine; Humans; Inflammasomes; Male; Mice; Mice, Inbred C57BL; NLR Family, Pyrin Domain-	2021
Improving the ameliorative effects of berberine and curcumin combination via dextran-coated bilosomes on non-alcohol fatty liver disease in mice. Journal of nanobiotechnology, 2021, Aug-04, Volume: 19, Issue:1 Topics: Administration, Oral; Animals; Berberine; Biological Availability; Caco-2 Cells; Curcumin; Dextrans;	2021
Berberine ameliorates fatty acid-induced oxidative stress in human hepatoma cells. Scientific reports, 2017, 09-12, Volume: 7, Issue:1 Topics: Berberine; Carcinoma, Hepatocellular; Cell Line, Tumor; Diet, High-Fat; Fatty Acids; Hepatocytes; Hu	2017
Natural products berberine and curcumin exhibited better ameliorative effects on rats with non-alcohol fatty liver disease than lovastatin. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 99 Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Berberine; Biologi	2018
Berberine alleviates hepatic lipid accumulation by increasing ABCA1 through the protein kinase C δ pathway. Biochemical and biophysical research communications, 2018, 04-06, Volume: 498, Issue:3 Topics: Animals; ATP Binding Cassette Transporter 1; Berberine; Cell Line; Hepatocytes; Humans; Lipid Metabo	2018
Inhibition of CCL19 benefits non‑alcoholic fatty liver disease by inhibiting TLR4/NF‑κB‑p65 signaling. Molecular medicine reports, 2018, Volume: 18, Issue:5 Topics: Alanine Transaminase; AMP-Activated Protein Kinase Kinases; Animals; Aspartate Aminotransferases; Be	2018
Berberine alleviates nonalcoholic fatty liver induced by a high-fat diet in mice by activating SIRT3. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2019, Volume: 33, Issue:6 Topics: Acetylation; Acyl-CoA Dehydrogenase, Long-Chain; Animals; Berberine; Carnitine; Diet, High-Fat; Drug	2019
Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway. Current medical science, 2019, Volume: 39, Issue:1 Topics: Acetyl-CoA Carboxylase; Adenylate Kinase; Animals; Berberine; Carnitine O-Palmitoyltransferase; Diet	2019
Berberine promotes the recruitment and activation of brown adipose tissue in mice and humans. Cell death & disease, 2019, 06-13, Volume: 10, Issue:6 Topics: Adipocytes; Adipose Tissue, Brown; Adult; AMP-Activated Protein Kinases; Animals; Anti-Obesity Agent	2019
Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway. Free radical biology & medicine, 2019, Volume: 141 Topics: AMP-Activated Protein Kinases; Animals; Berberine; Biopsy; Fatty Liver; Glucose Tolerance Test; Hep	2019
Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles. Journal of translational medicine, 2015, Jan-27, Volume: 13 Topics: Animals; Berberine; Cell Line, Tumor; Cluster Analysis; Diet, High-Fat; Feeding Behavior; Gene Expre	2015
[Intervention of berberine on lipid deposition in liver cells of non-alcoholic fatty liver disease rats induced by high fat diet]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2015, Volume: 35, Issue:3 Topics: Animals; Berberine; Diet, High-Fat; Down-Regulation; Drugs, Chinese Herbal; Fatty Liver; Hepatocytes	2015
Effect of a high fat, high sucrose diet on the promotion of non-alcoholic fatty liver disease in male rats: the ameliorative role of three natural compounds. Lipids in health and disease, 2015, Jul-31, Volume: 14 Topics: Animals; Berberine; Biological Products; Coumaric Acids; Diet, High-Fat; Feeding Behavior; Lipids; L	2015
Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress. Scientific reports, 2016, Feb-09, Volume: 6 Topics: Activating Transcription Factor 6; Animals; Berberine; Cell Line; Endoplasmic Reticulum Stress; Hepa	2016
Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice. Archives of Iranian medicine, 2016, Volume: 19, Issue:3 Topics: Animals; Berberine; Body Weight; Cytokines; Diet, High-Fat; Disease Models, Animal; Gastrointestinal	2016
Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice. Archives of Iranian medicine, 2016, Volume: 19, Issue:3 Topics: Animals; Berberine; Body Weight; Cytokines; Diet, High-Fat; Disease Models, Animal; Gastrointestinal	2016
Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice. Archives of Iranian medicine, 2016, Volume: 19, Issue:3 Topics: Animals; Berberine; Body Weight; Cytokines; Diet, High-Fat; Disease Models, Animal; Gastrointestinal	2016
Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice. Archives of Iranian medicine, 2016, Volume: 19, Issue:3 Topics: Animals; Berberine; Body Weight; Cytokines; Diet, High-Fat; Disease Models, Animal; Gastrointestinal	2016
Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet-induced Obesity. Scientific reports, 2016, Mar-03, Volume: 6 Topics: Acetyl-CoA Carboxylase; Adipose Tissue; AMP-Activated Protein Kinases; Animals; Berberine; Dietary F	2016
Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress. Biochemical and biophysical research communications, 2016, Apr-15, Volume: 472, Issue:4 Topics: AMP-Activated Protein Kinases; Animals; Antioxidants; Berberine; Enzyme Activation; Hep G2 Cells; Hu	2016
Activation of AMPK by berberine induces hepatic lipid accumulation by upregulation of fatty acid translocase CD36 in mice. Toxicology and applied pharmacology, 2017, 02-01, Volume: 316 Topics: AMP-Activated Protein Kinases; Animals; Berberine; CD36 Antigens; Enzyme Activators; Hep G2 Cells; H	2017
Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease. BMC endocrine disorders, 2017, Feb-28, Volume: 17, Issue:1 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Berberine; Carbohydrate Metabolism; Diet, High-Fat	2017
Effect of berberine on expressions of uncoupling protein-2 mRNA and protein in hepatic tissue of non-alcoholic fatty liver disease in rats. Chinese journal of integrative medicine, 2011, Volume: 17, Issue:3 Topics: Animals; Berberine; Cholesterol; Disease Models, Animal; Fatty Liver; Gene Expression Regulation; Io	2011
Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver. European journal of pharmacology, 2011, Oct-15, Volume: 668, Issue:3 Topics: Animals; Berberine; Fatty Liver; Gene Expression Regulation; Humans; Hypoglycemic Agents; Insulin Re	2011

berberine and Fatty Liver, Nonalcoholic